Hansa Biopharma AB: Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation
LUND, Sweden, June 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained
Source: finanznachrichten.de